Navigation Links
Essentialis to Submit SPA for Hypertriglyceridemia
Date:8/11/2009

CARLSBAD, Calif., Aug. 11 /PRNewswire/ -- Essentialis, Inc., a clinical stage pharmaceutical company, announced today its intention to file a Special Protocol Assessment (SPA) with the FDA for the pivotal study to support the NDA filing on its lead drug, DCCR, for the treatment of very high triglycerides. The proposed study would include 280 randomized subjects with the primary efficacy endpoint assessed at 12 weeks. This decision followed a productive Type C meeting with the FDA on July 30th, where the overall development plan for DCCR and the non-clinical package supporting the NDA were reviewed and discussed. Commenting on this development, Essentialis President and CEO Iain Dukes stated, "The submission of the SPA will bring us one step closer towards filing for approval of DCCR for the treatment of patients with very high triglycerides. This development, along with positive Phase 2 study results and the recent issuance of a US patent providing extensive protection to DCCR, underscores the tremendous clinical and commercial potential of this drug worldwide."

About DCCR

DCCR, diazoxide choline controlled release tablet, is an ATP-sensitive potassium channel agonist which has potential therapeutic utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing has demonstrated the drug's potential to lower triglycerides (TG), non-HDL cholesterol and LDL-cholesterol (LDL-C) while raising HDL-cholesterol. In addition, weight loss has been demonstrated in 2 investigator sponsored studies. A Phase 2, 8-week, placebo-controlled, double-blind study involving 90 patients, which was powered to be pivotal, demonstrated statistically significant reductions in triglycerides, without impacting LDL-C. In subjects with elevated LDL-C at baseline, DCCR reduced LDL-C levels. DCCR was generally well tolerated, and most AEs were mild to moderate, resolving without sequelae. US patent 7,572,789, containing claims to DCCR, was issued on August 11, 2009. Additional applications filed in the US and globally will further enhance the patent portfolio. Phase 2 and pivotal studies of DCCR in combination with a statin for the treatment of high triglycerides (TG between 200 and 500 mg/dL) are planned, and study synopses have been provided to the FDA.

About Hypertriglyceridemia

Very high triglycerides (TG greater than or equal to 500mg/dL) are a risk factor for developing pancreatitis. There are approximately 3.8 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides are fenofibrate and omega-3 fatty acids. While effective, these compounds cause significant elevations in LDL-C. High triglycerides (TG between 200 and 500 mg/dL) are a risk factor for coronary heart disease even after LDL-C targets have been achieved.

About Essentialis, Inc.

Essentialis, Inc. is a pharmaceutical company based in Carlsbad, CA. The Company's products are targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The Company's lead product, DCCR, is set to commence pivotal studies in subjects with very high triglycerides. Essentialis is actively exploring its partnering options for DCCR.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
2. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
3. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
4. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
5. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):